BPC-157 vs MK-677
A comprehensive, data-driven comparison of BPC-157 (Body Protection Compound-157) and MK-677 (Ibutamoren). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | BPC-157 Body Protection Compound-157, PL 14736 | MK-677 Ibutamoren, Nutrobal |
|---|---|---|
| FDA Status | Category 2 (pending reclassification) | Phase 2 |
| Category | Recovery & Healing | Growth Hormone |
| Primary Use | Tissue healing and injury recovery | Growth hormone optimization and muscle growth |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $50 - $120/mo | $50 - $100/mo |
| Administration | Subcutaneous injection | Oral |
| Typical Dose | 250-500mcg daily | 10-25mg daily |
| Frequency | Daily | Daily |
| Mechanism | Synthetic peptide derived from gastric juice protein that promotes angiogenesis, modulates growth factors, and accelerates tissue repair | Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Low | Moderate |
| Clinical Trial Phase | N/A | Phase 2 |
Key Differences
- 1MK-677 is generally more affordable ($50 - $100/mo) compared to BPC-157 ($50 - $120/mo).
- 2BPC-157 is administered via subcutaneous injection, while MK-677 uses oral.
- 3MK-677 has moderate-quality evidence, while BPC-157 has low-quality evidence.
- 4They belong to different categories: BPC-157 (Recovery & Healing) vs MK-677 (Growth Hormone).
Which Is Better For...
MK-677
More budget-friendly option with lower monthly costs
BPC-157
Fewer commonly reported side effects
MK-677
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| BPC-157 | $50 - $120/mo | Category 2 (pending reclassification) | Various research labs |
| MK-677 | $50 - $100/mo | Phase 2 | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
BPC-157 works via Synthetic peptide derived from gastric juice protein that promotes angiogenesis, modulates growth. MK-677 works via Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1. They differ in FDA approval status, efficacy data, and cost.
BPC-157 typically costs $50 - $120/mo, while MK-677 costs $50 - $100/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
BPC-157 is not FDA-approved (Category 2 (pending reclassification)). MK-677 is not FDA-approved (Phase 2). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of BPC-157 include Injection site discomfort, Mild headache, Dizziness. Common side effects of MK-677 include Increased appetite, Water retention, Fatigue. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
BPC-157 is a synthetic peptide consisting of 15 amino acids derived from a protective protein found in human gastric juice. Although not FDA-approved, it has gained significant attention in research a...
View Full BPC-157 GuideMK-677 (Ibutamoren) is an orally-active growth hormone secretagogue that mimics the action of ghrelin. Unlike peptide injections, it is taken orally and has a long half-life allowing once-daily dosing...
View Full MK-677 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between BPC-157 and MK-677 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.